hydroxyurea has been researched along with Cholera Infantum in 16 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 9.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "This study aims to determine the maximum tolerated dose (MTD) of clofarabine combined with the EORTC-GIMEMA 3 + 10 induction regimen (idarubicin + cytosine arabinoside) in adults with untreated acute myelogenous leukemia or high-risk myelodysplastic syndrome." | 5.19 | Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p ( Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R, 2014) |
| "In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)." | 5.07 | Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993) |
| "A 34% response was obtained in 202 evaluable patients in the terminal phase of chronic granulocytic leukemia using combinations of hydroxyurea, 6-mercaptopurine, and corticosteroids." | 3.66 | Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. ( Cavalli, F; Coleman, M; Glidewell, O; Holland, JF; Kostinas, JE; Pajak, TF; Rai, KR; Silver, RT, 1980) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "Hydroxyurea has documented laboratory efficacy with increases in Hb and HbF; treatment also significantly reduces the number of painful episodes, acute chest syndrome, transfusions, and hospitalizations." | 2.49 | Hydroxycarbamide: clinical aspects. ( Ware, RE, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (43.75) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ware, RE | 1 |
| Willemze, R | 1 |
| Suciu, S | 1 |
| Muus, P | 1 |
| Halkes, CJ | 1 |
| Meloni, G | 1 |
| Meert, L | 1 |
| Karrasch, M | 1 |
| Rapion, J | 1 |
| Vignetti, M | 1 |
| Amadori, S | 1 |
| de Witte, T | 1 |
| Marie, JP | 1 |
| Noronha, SA | 1 |
| Sadreameli, SC | 1 |
| Strouse, JJ | 1 |
| Ballas, SK | 1 |
| Kesen, MR | 1 |
| Goldberg, MF | 1 |
| Lutty, GA | 1 |
| Dampier, C | 1 |
| Osunkwo, I | 1 |
| Wang, WC | 1 |
| Hoppe, C | 1 |
| Hagar, W | 1 |
| Darbari, DS | 1 |
| Malik, P | 1 |
| Kühr, T | 1 |
| Burgstaller, S | 1 |
| Apfelbeck, U | 1 |
| Linkesch, W | 1 |
| Seewann, H | 1 |
| Fridrik, M | 1 |
| Michlmayr, G | 1 |
| Krieger, O | 1 |
| Lutz, D | 1 |
| Lin, W | 1 |
| Pont, J | 1 |
| Köck, L | 1 |
| Abbrederis, K | 1 |
| Baldinger, C | 1 |
| Buder, R | 1 |
| Geissler, D | 1 |
| Hausmaninger, H | 1 |
| Lang, A | 1 |
| Zabernigg, A | 1 |
| Duba, C | 1 |
| Hilbe, W | 1 |
| Eisterer, W | 1 |
| Fiegl, M | 1 |
| Greil, R | 1 |
| Gastl, G | 1 |
| Thaler, J | 1 |
| Louvet, C | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 1 |
| Gamelin, E | 1 |
| de Gramont, A | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Mittelman, A | 1 |
| Klaassen, DJ | 1 |
| Pfeifle, CE | 1 |
| Howell, SB | 1 |
| Spry, CJ | 1 |
| Coleman, M | 1 |
| Silver, RT | 1 |
| Pajak, TF | 1 |
| Cavalli, F | 1 |
| Rai, KR | 1 |
| Kostinas, JE | 1 |
| Glidewell, O | 1 |
| Holland, JF | 1 |
| Cvitkovic, FB | 1 |
| Haie-Meder, C | 1 |
| Papadimitrakopoulou, V | 1 |
| Armand, JP | 1 |
| Cioloca, C | 1 |
| Maugis, N | 1 |
| Constans, JP | 1 |
| Higashigawa, M | 1 |
| Hori, H | 1 |
| Hirayama, M | 1 |
| Kawasaki, H | 1 |
| Ido, M | 1 |
| Azuma, E | 1 |
| Sakurai, M | 1 |
| Hillyer, MH | 1 |
| Mair, TS | 1 |
| Ottolenghi, F | 1 |
| Andreassi, L | 1 |
| Piver, MS | 1 |
| Barlow, JJ | 1 |
| Vongtama, V | 1 |
| Webester, J | 1 |
| Richards, GJ | 1 |
| Chambers, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for hydroxyurea and Cholera Infantum
| Article | Year |
|---|---|
Hydroxycarbamide: clinical aspects.
Topics: Agranulocytosis; Anemia, Sickle Cell; Antisickling Agents; Clinical Trials as Topic; Developing Coun | 2013 |
Management of Sickle Cell Disease in Children.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child; Gastrointestinal Diseases; Heart Diseases; Humans; | 2016 |
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
Topics: Anemia, Sickle Cell; Blood Transfusion; Clinical Trials as Topic; Disease Management; Gastrointestin | 2012 |
The hypereosinophilic syndrome: clinical features, laboratory findings and treatment.
Topics: Anticoagulants; Bone Marrow; Central Nervous System Diseases; Endomyocardial Fibrosis; Eosinophilia; | 1982 |
5 trials available for hydroxyurea and Cholera Infantum
| Article | Year |
|---|---|
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides | 2014 |
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gastrointestinal Di | 2003 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1993 |
Hydroxyurea and radiation therapy in advanced cervical cancer.
Topics: Anemia, Aplastic; Clinical Trials as Topic; Drug Eruptions; Drug Evaluation; Evaluation Studies as T | 1974 |
7 other studies available for hydroxyurea and Cholera Infantum
| Article | Year |
|---|---|
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
Phase I trial of cytarabine and hydroxyurea.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Child; Cy | 1983 |
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.
Topics: Daunorubicin; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Human | 1980 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Co | 1997 |
Multisystemic eosinophilic epitheliotropic disease in a horse: attempted treatment with hydroxyurea and dexamethasone.
Topics: Animals; Dexamethasone; Eosinophilia; Epithelium; Female; Gastrointestinal Diseases; Horse Diseases; | 1992 |
[Limitations and risks of therapy of psoriasis with amethopterin and hydroxyurea].
Topics: Adult; Aged; Blood Coagulation Disorders; Chemical and Drug Induced Liver Injury; Chromosome Aberrat | 1971 |
Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck.
Topics: Adult; Age Factors; Aged; Female; Gastrointestinal Diseases; Head; Head and Neck Neoplasms; Hematolo | 1969 |